S
Stefano Colloca
Researcher at Merck & Co.
Publications - 88
Citations - 6375
Stefano Colloca is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Antigen. The author has an hindex of 40, co-authored 81 publications receiving 5766 citations.
Papers
More filters
Journal ArticleDOI
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
Eleanor Barnes,Eleanor Barnes,Antonella Folgori,Stefania Capone,Leo Swadling,Stephen Aston,Ayako Kurioka,Joel Meyer,Rachel Huddart,Kira Smith,Rachel Townsend,Anthony Brown,Richard D Antrobus,Virginia Ammendola,M. Naddeo,Geraldine O'Hara,C Willberg,Abby Harrison,Fabiana Grazioli,Maria Luisa Esposito,Loredana Siani,Cinzia Traboni,Ye Oo,David H. Adams,Adrian V. S. Hill,Adrian V. S. Hill,Stefano Colloca,Alfredo Nicosia,Riccardo Cortese,Paul Klenerman,Paul Klenerman +30 more
TL;DR: It is demonstrated that vaccines developed with adenoviral vectors can induce broad and sustained immune responses to HCV in humans and open the way for studies of prophylactic and therapeutic vaccines for HCV.
Journal ArticleDOI
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.
Antonella Folgori,Stefania Capone,Lionello Ruggeri,Annalisa Meola,Elisabetta Sporeno,Bruno Bruni Ercole,Monica Pezzanera,Rosalba Tafi,Mirko Arcuri,Elena Fattori,Armin Lahm,Alessandra Luzzago,Alessandra Vitelli,Stefano Colloca,Riccardo Cortese,Alfredo Nicosia +15 more
TL;DR: The findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV or malaria, which can evade humoral responses.
Journal ArticleDOI
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Daphne A. Stanley,Anna N. Honko,Anna N. Honko,Clement Asiedu,John C. Trefry,Annie W. Lau-Kilby,Joshua C. Johnson,Joshua C. Johnson,Lisa E. Hensley,Lisa E. Hensley,Virginia Ammendola,Adele Abbate,Fabiana Grazioli,Kathryn E. Foulds,Cheng Cheng,Lingshu Wang,Mitzi M. Donaldson,Stefano Colloca,Antonella Folgori,Mario Roederer,Gary J. Nabel,John R. Mascola,Alfredo Nicosia,Riccardo Cortese,Richard A. Koup,Nancy J. Sullivan +25 more
TL;DR: It is shown that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques, and generated, for the first time, durable protection against lethal E BOV challenge.
Journal ArticleDOI
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
Katie J. Ewer,Tommy Rampling,N Venkatraman,Georgina Bowyer,Daniel B. Wright,Teresa Lambe,Egeruan B. Imoukhuede,Ruth O. Payne,Sarah Katharina Fehling,Thomas Strecker,Nadine Biedenkopf,Verena Krähling,Claire M. Tully,Nick J. Edwards,Emma M. Bentley,Dhanraj Samuel,Geneviève M. Labbé,Jing Jin,Malick M. Gibani,Alice Minhinnick,Morven Wilkie,Ian D. Poulton,Natalie Lella,Rachel Roberts,Felicity Hartnell,Carly M. Bliss,Kailan Sierra-Davidson,Jonathan Powlson,Eleanor Berrie,Richard S. Tedder,François Roman,Iris De Ryck,Alfredo Nicosia,Nancy J. Sullivan,Daphne A. Stanley,Olivier Tshiani Mbaya,Julie E. Ledgerwood,Richard M. Schwartz,Loredana Siani,Stefano Colloca,Antonella Folgori,Stefania Di Marco,Riccardo Cortese,Edward Wright,Stephan Becker,Barney S. Graham,Richard A. Koup,Myron M. Levine,Ariane Volkmann,Paul Chaplin,Andrew J. Pollard,Simon J. Draper,W. Ripley Ballou,Alison M. Lawrie,Sarah C. Gilbert,Adrian V. S. Hill +55 more
TL;DR: The chimpanzee adenovirus 3 (ChAd3) vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were superior to those induced by the ChAd3 vaccine alone.
Journal ArticleDOI
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Leo Swadling,Stefania Capone,Richard D Antrobus,Anthony Brown,Rachel Richardson,Evan W. Newell,Evan W. Newell,John Halliday,John Halliday,Christabel Kelly,Christabel Kelly,Dan Hameiri Bowen,Joannah R. Fergusson,Ayako Kurioka,Virginia Ammendola,Mariarosaria Del Sorbo,Fabiana Grazioli,Maria Luisa Esposito,Loredana Siani,Cinzia Traboni,Adrian V. S. Hill,Stefano Colloca,Mark M. Davis,Alfredo Nicosia,Riccardo Cortese,Antonella Folgori,Paul Klenerman,Paul Klenerman,Eleanor Barnes,Eleanor Barnes +29 more
TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.